It looks like on Merck's website they are currentl
Post# of 154722
(Total Views: 698)
Posted On: 05/20/2024 8:26:28 PM
Re: HouseofCards #143456
Quote:
It looks like on Merck's website they are currently recruiting for a couple CRC trials.
I took a look at those trials.
One is a solid tumor basket trial including CRC that just uses Keytruda. We know leronlimab does what Keytruda does.
One is a solid tumor basket trial that uses Keytruda and Belzutifan which inhibits HIF-2a. HIF-1a was on the leronlimab regulator list but not HIF-2a. I took a look at the HIF-2a pathway and leronlimab would downregulate it via downregulation of NF-kb.
The third trial is in CRC but it's looking at microsatellite instability CRC rather than microsatellite stable CRC like our trial. Merck's trial pairs Keytruda with Quavonlimab which blocks CTLA-4. CTLA-4 is on the leronlimab regulator list.
Merck's going about this all wrong. They need a trial pairing Keytruda with a couple of dozen drugs then they can approach what leronlimab does.
(19)
(0)